Completed trial compares Iheezo to standard anesthesia for intravitreal injections, lists Harrow as
A single-site, phase 4 study run by Retina Consultants of Delmarva finished in August 2026, with Harrow Inc named as collaborator on the registry record.
- "Comparative Evaluation of Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia in a Private Retina Practice" (NCT07779356) is a completed, phase 4 randomized study sponsored by Retina Consultants of Delmarva with Harrow Inc as collaborator. The trial enrolled 100 eyes from 50 patients who each received bilateral same-day intravitreal injections, with Iheezo given to one randomly selected eye and standard topical anesthesia given to the other eye.1 The record's primary completion date is 2026-08-07 and it was first posted 2026-08-21.
Fact check notes
- Checker's noteThe claim that Iheezo is Harrow Inc's 'product' is not explicitly supported by the registry record, which only lists Harrow Inc as a collaborator, not as the drug's manufacturer or owner.
- Sentence removed
The week's registry activity for Harrow Inc consists of one completed study examining patient comfort with its product Iheezo.
unsupported: The source does not state that Iheezo is Harrow Inc's product; Harrow is only listed as a collaborator, not as manufacturer/owner of Iheezo.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.